News - Financing risk management - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

Company news

Wang Xingxing of Unitree Leads Newcomers on Fortune China 40 Under 40

Today, Fortune (Chinese edition) officially released the "2026 Fortune China 40 Under 40" list. Zhu Pai, CEO of Efung Capital, was honored to be included.Since its establishment in 2011, the list has continued to spotlight Chinas younger generation of innovators and value creators. Among past honorees, names such as Pony Ma, Chairman of the Board and CEO of Tencent; Richard Liu, Chairman of the Board of JD.com; and Liang Wenfeng, founder of DeepSeek, have since profoundly influenced Chinese business.Among this years 40 honorees, business elites including Wang Xingxing, founder, chairman, CEO and CTO of Unitree; Yang Zhilin, founder and CEO of Moonshot AI (Kimi); and Zhang Xue, founder and CEO of Zhangxue Motorcycles, were honored. A total of 18 are directly involved in AI and embodied intelligence, while the other 22 come from fields such as new energy, healthcare, new consumer, and investment. Their industries differ, but one common trend stands out: AI is becoming a foundat...

2026 - 09 - 23
Together Embarking on a New Journey for the 15th Five-Year Plan | Efung Capital and Its Portfolio Companies Appear at the 2026 Shenzhen High-Performance Medical Device Exhibition

September 21–23, the 2026 Shenzhen International High-Performance Medical Device Exhibition and Innovative Pharmaceutical Exhibition grandly opened at Hall 1 of the Shenzhen Convention and Exhibition Center (Futian).This exhibition is hosted by the Shenzhen Medical Device Industry Association and the National High-Performance Medical Device Innovation Center, with the Shenzhen Municipal Development and Reform Commission (Shenzhen Pharmaceutical and Medical Device Industry Office), the Shenzhen Municipal Health Commission, and the Shenzhen Municipal Healthcare Security Bureau as supporting units. It covers all links of the industrial chain, including upstream core components and supply chain support, high-end equipment and innovative drugs and devices, and distribution services and clinical application.The exhibition features specialized zones such as high-end medical devices, innovative pharmaceuticals, and university/hospital achievement transformation, centrally showcasing Shenzhens ...

2026 - 09 - 21
3.5 Trillion Yuan! China's 2030 Goal for the Pharmaceutical Industry

Chinas Ministry of Industry and Information Technology, together with nine other government departments, recently issued the "15th Five-Year Plan for the Development of the Pharmaceutical Industry."The plan proposes that by 2030, Chinas biopharmaceutical R&D and application shall rank among the worlds leading positions, the effectiveness of innovation-driven development shall be fully unleashed, and systematic breakthroughs shall be achieved in key core technologies in priority fields. Core competitiveness and international influence shall rise substantially. The biopharmaceutical industry shall accelerate its transformation into a new pillar industry of the nation, continuously safeguarding and enhancing the peoples life and health.The plan sets out ten anticipated indicators, including: by 2030, the operating revenue of pharmaceutical industrial enterprises above designated size shall be no less than 3.5 trillion yuan; the proportion of first-in-class (FIC) drugs origin...

2026 - 09 - 18
Hong Kong's First Five-Year Plan Unveiled! The Healthy Greater Bay Area Ushers in a Golden Five Years | Efung Knowledge Planet

Full text: approx. 2,191 Chinese characters | Reading time: approx. 3 minutesOn September 16, John Lee, Chief Executive of the Hong Kong Special Administrative Region, announced the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026–2030) (hereinafter referred to as the "Plan") at the Legislative Council meeting, and subsequently delivered his fifth Policy Address during his term.【1】This is the first five-year plan formulated since Hong Kongs return to the motherland.When explaining the relationship between the two documents, John Lee stated: The Plan is the blueprint for Hong Kongs economic and social development over the next five years, serving as a forward-looking, strategic, and directional guiding document; the Policy Address is the Chief Executives annual report on the implementation of the five-year plan, as well as the annual policy priorities and major projects in response to actual circumstances. The two ar...

2026 - 09 - 17
Efung Hardcore Sharing | From Targeting Proteins to Targeting RNA: How AI is Unlocking the Druggable Space of the Transcriptome

Modern drug discovery is built on an implicit premise: drugs act on proteins. Whether small molecules or antibodies, the essence is to find a pocket or epitope on a disease-causing protein, then bind to it and inhibit it. This paradigm has supported the pharmaceutical industry for nearly a century, and it is now approaching its ceiling—only about 1.5% of the human genome encodes proteins, of which only about ten percent are disease-related, and fewer than 700 proteins have actually been targeted by approved drugs globally to date. The vast majority of remaining disease-causing proteins—transcription factors, scaffold proteins, "undruggable" targets lacking active pockets—are beyond the reach of traditional methods. The "low-hanging fruit" has been picked clean, and protein targets are being exhausted.Since proteins are difficult to tackle, why not move upstream to the RNA that encodes them—this is a natural thought. But what truly blocks this path is an old problem ...

2026 - 09 - 15
Bridging with Capital to Forge a New Global Biotech Paradigm | Dr. Jinqiao Zhu of Evident Partners Speaks at BIOHK 2026

From September 9 to 12, 2026, the 5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK 2026) was held at the Hong Kong Convention and Exhibition Centre. This year’s theme is Kaleidoscope, symbolizing a panoramic view of the industry from diverse perspectives — which mirrors the current landscape of China’s innovative drug sector: policy frameworks, capital logic and technological paradigms are all undergoing a shift. What the industry needs now is no longer a simplistic narrative, but judgment capable of weathering market cycles. Dr. Jinqiao Zhu, Founder & Chairman of Evident Partners, was invited to the summit to deliver a keynote speech and join a panel discussion.01 From “Financing Gateway” to “Pricing Hub”:Hong Kong’s Structural EvolutionAs the world’s third-largest financial centre, Hong Kong maintained robust IPO momentum in the first half of 2026, welcoming 87 new listed companies. It ranked second globally both by the number of IPOs and total capital r...

2026 - 09 - 12

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务